Press release article from our research archive:

AVAX Provides Regulatory Update.

KANSAS CITY, Mo., April 23 /PRNewswire Interactive News Release/ --

AVAX Technologies, Inc. (Nasdaq: AVXT) announced today that it has received written notifications from the U.S. Food and Drug Administration (FDA) confirming the previously-reported clinical hold of AVAX's M-Vax and O-Vax autologous cancer vaccine clinical trials. The written notifications contain numerous FDA comments, questions and requests for additional information concerning the M-Vax and O-Vax products and clinical trials, and goes beyond the scope of prior oral communications from the FDA. The FDA request for additional information, while including issues related to the sterility of tumor cells ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!